A new HIV prevention shot, approved by the FDA and taken just twice a year, could transform global care, but experts warn ...

In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses KITE-363, an anti-CD19/CD20 chimeric antigen receptor T-cell therapy, being studied for patients with ...

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The Food and Drug Administration approved a new vaccine to prevent HIV infection, lenacapavir, a long-acting injection, which ...

Spread This NewsBy Lauran Neergaard I Associated Press THE U.S. has approved the world’s only twice-a-year shot to prevent ...

The Food and Drug Administration has approved a new, first-of-its-kind semiannual HIV prevention medication, Gilead Sciences ...

The US Food and Drug Administration (FDA) on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of ...

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The approval of Lenacapavir – a twice-yearly antiviral HIV-preventing medication marketed under the brand name Yeztugo – by the US Food and Drug Administration (FDA), has been welcomed by the global ...

The United States Food and Drug Administration (FDA) has approved a twice-a-year injectable drug to be used for HIV ...